Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Regorafenib

FDA-approved product (tablet, oral), marketed as Regorafenib, Stivarga.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Regorafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Regorafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Regorafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy

    NCT01959269 · start 2013-10-31

    Registered record
    Registry ID
    NCT01959269
    Conditions
    Colorectal Neoplasm
    Interventions
    Regorafenib (Stivarga, BAY 73-4506)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-10-31
    Completion
    2017-07-07
    Enrolment
    483

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasm
    InterventionRegorafenib (Stivarga, BAY 73-4506)
    PhaseNot recorded
    Registry statusCompleted

  • Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers

    NCT01949194 · start 2013-09

    Registered record
    Registry ID
    NCT01949194
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2013-09
    Completion
    2018-12
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionRegorafenib
    PhasePhase 2
    Registry statusUnknown

  • Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma

    NCT01900743 · start 2013-06-05

    Registered record
    Registry ID
    NCT01900743
    Conditions
    Sarcoma
    Interventions
    Regorafenib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-06-05
    Completion
    2020-09-16
    Enrolment
    219

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    InterventionRegorafenib; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines

    NCT01786538 · start 2013-06

    Registered record
    Registry ID
    NCT01786538
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    Regorafenib/FOLFOX; Placebo/FOLFOX
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2013-06
    Completion
    2017-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionRegorafenib/FOLFOX; Placebo/FOLFOX
    PhasePhase 3
    Registry statusWithdrawn

  • WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib

    NCT01265979 · start 2011-01

    Registered record
    Registry ID
    NCT01265979
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    Whole body diffusion MRI
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-01
    Completion
    2011-09
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    InterventionWhole body diffusion MRI
    PhaseNot recorded
    Registry statusCompleted